Copanlisib + Rituximab
Phase 2Active 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Marginal Zone Lymphoma
Conditions
Marginal Zone Lymphoma
Trial Timeline
Dec 15, 2019 → Dec 31, 2027
NCT ID
NCT03474744About Copanlisib + Rituximab
Copanlisib + Rituximab is a phase 2 stage product being developed by Celltrion for Marginal Zone Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT03474744. Target conditions include Marginal Zone Lymphoma.
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03474744 | Phase 2 | Active |
Competing Products
10 competing products in Marginal Zone Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Rituximab + Pembrolizumab | Celltrion | Phase 2 | 27 |
| Pirtobrutinib + Rituximab | Eli Lilly | Phase 2 | 42 |
| Epcoritamab | AbbVie | Phase 2 | 42 |
| Rituximab + Venetoclax | AbbVie | Phase 2 | 39 |
| VAY736 + lenalidomide | Novartis | Phase 1 | 21 |
| PI3K inhibitor BKM120 + rituximab | Novartis | Phase 1 | 29 |
| Obinutuzumab | Roche | Phase 2 | 39 |
| Umbralisib | TG Therapeutics | Phase 2 | 32 |
| HMPL-689 | HUTCHMED | Phase 2 | 29 |
| Loncastuximab tesirine 150 µg/Kg + Loncastuximab tesirine 75µg/Kg | ADC Therapeutics | Phase 2 | 36 |